Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their antiinflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment.
Introduction
Cancer is the second leading cause of death in the United States and represents a significant health concern in most industrialized countries. A large body of evidence indicates that genetic mutations, epigenetic changes, diet, lifestyle and chronic inflammation are risk factors for cancer. Currently, the most effective treatments for cancer, including various combinations of surgical resection, radiation and/or chemotherapy, depend on the detection of cancer at a very early stage.
Unfortunately, it has not been possible to identify all individuals at the earliest stages of disease. In fact, most patients present to their physician with advanced cancer when standard treatments for solid malignancies result in a much lower 5-year survival. Thus, an effective approach for this disease must include prevention and targeted therapy. It is generally agreed that an effective way to control cancer is to find better ways of preventing it and/or detecting the disease at its earliest stage.
Colorectal cancer (CRC) is a heterogeneous disease. At least three major forms of CRC have been described: hereditary, sporadic and colitis-associated CRC. Patients with familial adenomatous polyposis (FAP), due to a germline mutation in one allele of the tumor suppressor gene adenomatous polyposis coli (APC), have a near 100% risk of developing CRC by the age of 40 years if untreated. Somatic mutation of APC occurs in about 85% of sporadic colorectal adenomas and carcinomas (Powell et al., 1992; Jen et al., 1994; Smith et al., 1994) . Hereditary nonpolyposis colorectal cancer, which is due to inherited mutations in genes for DNA mismatch repair such as MLH1, MSH2 and MSH6, is responsible for approximately 2-7% of all diagnosed cases of CRC. On average, patients with this syndrome develop cancer at around 44 years of age, compared with 64 years of age in the general population.
Chronic inflammation and aging are other risk factors associated with CRC development. The gastrointestinal mucosa forms a complex semipermeable barrier between the host and the largest source of foreign antigens. The mucosal immune system has the ability to mount an immune response to pathogens while maintaining tolerance to the vast array of benign luminal antigens from food and commensal bacteria. Many inflammatory processes are self-limiting, supporting the existence of endogenous anti-inflammatory mechanisms. An abnormal mucosal immune response is thought to result in chronic inflammation such as inflammatory bowel disease (IBD). IBD in humans is a complex group of disorders that has been grouped into two major forms, ulcerative colitis and Crohn's disease. These chronic conditions of the gut currently affect over 5 million people between the age of 16 and 40 years and cause significant morbidity in North American and Europe. In general, Crohn's disease has been considered to be Th1 (T helper) cell-mediated response, whereas ulcerative colitis is thought to be Th2 cellmediated response. However, a newly defined class of interleukin-17-producing CD4 þ T cells, termed Th17 cells, has been found to have a key role in Crohn's disease and may alter the notion of this Th1 and Th2 dichotomy in IBD (Harrington et al., 2006; Steinman, 2007) . Together with the hereditary syndromes of FAP and hereditary nonpolyposis CRC, IBD is among the top three high-risk conditions for CRC. In particular, chronic IBD (especially pan-colitis) significantly increases the risk of developing CRC (Lewis et al., 1999; Izzo and Camilleri, 2008) . Therefore, patients with IBD face an increased lifetime risk of developing CRC. Compared with other forms of CRC, colitis-associated CRC affects individuals at a younger age than the general population. As dysplasia in patients with IBD can be polypoid or flat, localized, diffuse or multifocal, syndromes of dysplasia in the colon indicate the entire colon as being at heightened risk of neoplasia. Unfortunately, the entire colon has to be surgically removed after detection of dysplasia in the colon. Therefore, clinical cancer surveillance in IBD patients is more challenging than in patients without IBD. Thus, an effective approach for this disease should consider chemopreventive approaches if proven beneficial.
Preventive effects of NSAIDs on CRC
A significant effort has been made to identify novel drug targets for CRC prevention and treatment. One group of compounds found to decrease the risk of CRC nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), which target the cyclooxygenase enzymes (COX-1 and COX-2). Although NSAIDs are some of the most commonly used drugs in the United States and around the world, the prolonged use of nonselective NSAIDs is associated with side effects such as nausea, dyspepsia, gastritis, abdominal pain, peptic ulcer, gastrointestinal bleeding and/or perforation of gastroduodenal ulcers (Wolfe et al., 1999) . As elevated COX-2 expression was found in approximately 50% of adenomas and 85% of adenocarcinomas (Eberhart et al., 1994; Gupta and DuBois, 2001; Marnett and DuBois, 2002) and is associated with worse survival among CRC patients (Ogino et al., 2008) , it was hypothesized that NSAIDs exert some of their anti-inflammatory and antitumor effects through inhibition of the inducible COX-2 (Vane et al., 1998; Grover et al., 2003) . The unwanted side effects of these drugs as mentioned above were postulated to arise from the inhibition of the constitutive COX-1 (Vane, 1971) . Therefore, investigators originally developed selective COX-2 inhibitors (COXIBs) such as celecoxib, rofecoxib and valdecoxib to overcome the gastrointestinal adverse events of nonselective NSAIDs that placed limits on effective therapy.
A large body of evidence from population-based studies, case-control studies and clinical trials indicate that regular use of NSAIDs including aspirin and COXIBs over a 10-to 15-year period reduces the relative risk of developing CRC by 40-50% (Flossmann and Rothwell, 2007; Rostom et al., 2007; Chan et al., 2008) . Aspirin use was associated with a risk reduction in patients whose colon tumors expressed higher levels of COX-2 (Chan et al., 2007) . In addition to prevention, regular aspirin use after the diagnosis of CRC at stage I, II and III improves overall survival, especially among individuals with tumors that overexpress COX-2 (Chan et al., 2009) , suggesting the potential therapeutic use of NSAIDs in advanced CRC. Furthermore, a randomized double-blind trial showed that NSAIDs have preventive effects on patients with previous polyps (Sandler et al., 2003; Bertagnolli et al., 2006) . These findings prompted investigators to evaluate the preventive effects and safety of COXIBs in patients with FAP or previous history of adenomas. The data from controlled trials showed that the use of NSAIDs leads to the regression of preexisting adenomas in patients with FAP (Rostom et al., 2007) . Particularly, the evidence that treatment of FAP patients with celecoxib significantly reduced the polyp burden in a randomized controlled trial led to the Food and Drug Administration approval of celecoxib (brand name Celebrex) for use in patients with FAP at 400 mg twice a day (Steinbach et al., 2000) . Furthermore, three large double blind randomized controlled trials, including the Adenoma Prevention with Celecoxib (APC) trial (Bertagnolli et al., 2006) , the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (Arber et al., 2006) and the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial (Bresalier et al., 2005) , were performed and showed that COXIBs prevent recurrence of sporadic adenomas with an increase in cardiovascular events. In the trials with celecoxib, a 2.5-to 3-fold increased relative risk for cardiovascular thromboembolic events was observed with a 400 mg twice-daily dosing celecoxib schedule compared with placebo, whereas a once-daily dosing schedule or 200 mg twicedaily dosing showed much less risk rate compared with placebo , indicating a trend for a dose-related increase in cardiovascular events. However, the detailed analysis of the APC trial found that a history of atherosclerotic heart disease was the only specific risk factor associated significantly with celecoxib to adverse cardiovascular events (Bertagnolli et al., 2009) . Furthermore, a recent pooled analysis of adjudicated data from six placebo-controlled trials further showed that the celecoxib-related cardiovascular risk is positively correlated with the drug dose and the baseline cardiovascular risk (pretreatment cardiovascular status) in patients (Solomon et al., 2008) . More intriguingly, a recent report that retrieved all existing epidemiological studies (case-control and cohort studies) from 1980 shows that regular intake of NSAIDs significantly reduced the risk for colorectal, breast, lung and prostate cancer (Harris, 2009) . The most important finding from this report is that the meta-analysis of independent estimates from 72 studies provides no evidence that daily use of the celecoxib increases the relative risk of cardiovascular disease. Another cohort study examined cardiovascular outcomes in approximately 1.4 million patients receiving NSAIDs or COXIBs showed that there was, again, no risk observed COX-2 in IBD and CRC D Wang and RN DuBois with celecoxib (Graham et al., 2005) . Therefore, it is necessary to further assess the relative risks and benefits of celecoxib in different clinical settings such as people with or without vascular disease and patients with adenomas. As all drugs are associated with some risk, any therapy has to weigh the potential risk against the potential benefit.
Another approach for decreasing the undesired side effects of COXIBs is to lower the drug dose used. The combinational treatment of NSAIDs with different agents that target key signaling pathways involved in cancer progression have been evaluated. It has been demonstrated that the epidermal growth factor receptor (EGFR) signaling pathway is involved in many different types of cancer, including colorectal, breast and lung cancer (Kelloff et al., 1996) . EGFR activity has been associated with adenoma growth in Apc Min/ þ mice (Moran et al., 2004) and disruption of EGFR signaling through either kinase inhibition or genetic mutation inhibits polyp formation as well as the growth of established tumors (Roberts et al., 2002) . Recent evidence showed that combined treatment with celecoxib and erlotinib (an EGFR tyrosine kinase inhibitor) was more effective in preventing polyp formation in Apc Min/ þ mice and more significant inhibition of tumor growth in a xenograft model than either drug individually (Buchanan et al., 2007) . Moreover, a phase I clinical trial was recently completed to evaluate the optimal biological dose of celecoxib in combination with erlotinib in patients with advanced non-small cell lung cancer (Reckamp et al., 2006) . This trial showed that there were no doselimiting toxicities and no cardiovascular toxicities related to celecoxib at the dosing ranges of 200-800 mg twice daily. Another phase I trial showed that combination of bortezomib (an inhibitor of ubiquitin-proteasome pathway) and celecoxib at the dosing ranges of 200-400 mg twice daily was well tolerated in patients with advanced solid tumors (Hayslip et al., 2007) . Similarly, a 5-lipoxygenase inhibitor overcame a resistance of tumor cell to a SC-236 (a COXIB) and restored the ability of SC-236 to inhibit tumor growth in an animal model of breast cancer (Barry et al., 2009) . Combined treatment using celecoxib and a peroxisome proliferatorsactivated receptor-g (PPARg) agonist was significantly more effective than either alone in a mouse model of spontaneous breast cancer (Anderson et al., 2009 ). In addition, combination therapy with aromatase inhibitors and celecoxib may have improved efficacy and had an acceptable safety profile in patients with metastatic breast cancer compared with monotherapy (Falandry et al., 2009 ). Finally, phase II studies in patients with metastatic breast cancer and advanced pancreatic carcinoma suggested that celecoxib may enhance clinical benefit with decreasing certain chemotherapy-related toxic effects and is well tolerated without excess cardiotoxicity at a dose of 400-800 mg/day for a limited period of time (Milella et al., 2004; Ferrari et al., 2006; Fabi et al., 2008) . These studies support the notion that combinations of different agents for cancer prevention and treatment may be more effective than single-agent therapy alone with minimal side affects.
COX-2 regulation
To date, COX-2 represents an important molecular target in CRC prevention and treatment. COX-2 is an immediate-early response gene normally absent from most cells but is induced mainly at sites of inflammation in response to inflammatory stimuli, including proinflammatory cytokines such as interleukin-1a/b, interferon-g and tumor necrosis factor-a produced by inflammatory cells. Tumor promoters such as tetradecanoyl phorbol acetate and mutant KRas (Dubois et al., 1998; Wang et al., 2005 ) also induce COX-2 expression. By contrast, COX-1 contributes to maintenance of the gastric mucosa, regulation of renal blood flow in the afferent vessels of the kidney and regulation of platelet aggregation.
Cyclooxygenase-2 expression is regulated at both the transcriptional and post-transcriptional levels. It is well established that the COX-2 transcription can be regulated by various transcription factors such as nuclear factor-kB, C/EBP, CREB, NFAT, AP-1 and PPAR. COX-2 mRNA is also modulated by posttranscriptional mechanisms through AU-rich regions in its 3
0 -untranslated region. The RNA-binding proteins Hu antigen R (HuR) and tristetraprolin (TTP) bind to AU-rich elements in the 3 0 -untranslated region of COX-2 to stabilize or to destabilize its mRNA, respectively (Young et al., 2009) . Recently, microRNAs have been suggested to silence COX-2 expression by translational repression and/or degradation of its mRNA through 3 0 -untranslated region (Daikoku et al., 2008; Strillacci et al., 2009) . In addition to the inflammatory microenvironment, a hypoxic environment also induces COX-2 expression in colorectal tumor cells through hypoxia-inducible factor-1a (Kaidi et al., 2006) . In contrast, a 2-arachidonoyl-glycerol (an endocannabinoid) is able to suppress elevation of COX-2 expression in response to proinflammatory and excitotoxic stimuli in neurons and astroglial cells (Zhang and Chen, 2008) . Caveolin-1 is a scaffold protein that has been proposed to function as a tumor suppressor in human cancer cells. Caveolin-1 downregulated COX-2 mRNA and protein levels as well as the production of PGE 2 and cell proliferation in human CRC cell lines (Rodriguez et al., 2009 ).
COX-2 and IBD
The proinflammatory enzyme, COX-2, is induced in the large intestine of IBD patients and in inflamed tissues of interleukin-10-deficient mice (a mouse model of IBD) (Singer et al., 1998; Shattuck-Brandt et al., 2000) . As both nonselective NSAIDs and COXIBs can be used to treat arthritis and reduce the risk of developing CRC, these agents might be expected to have anti-inflammatory and chemopreventive roles in IBD and IBDassociated CRC. Although the 5-aminosalicylate-based compounds have remained the mainstream for the treatment of IBD patients, evidence from clinical studies has shown conflicting data in treatment of IBD with other nonselective NSAIDs or COXIBs. In general,
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COXIBs have fewer gastrointestinal side effects than the nonselective NSAIDs (Felder et al., 2000; Mahadevan et al., 2002) . A recent double-blind and placebo-control study showed that etoricoxib (COXIB) therapy is safe and beneficial in most IBD patients without exacerbation of IBD-and gastrointestine-related complications (El Miedany et al., 2006) . Similar to the results from clinical studies, conflicting results have emerged regarding the effects of NSAIDs on IBD in animal models (Wang et al., 2005) . Genetic evidence showed that COX-2-deficient mice have increased sensitivity to chemically induced colitis (Morteau et al., 2000) . However, the recent observation that a combinational treatment of a COXIB and an inhibitor of nitric oxide synthase has a protective effect on chemically induced colitis supports the idea that simultaneous inhibition of nitric oxide synthase and COX-2 might have some potential in the treatment of colitis (Dudhgaonkar et al., 2007) . Therefore, further clinical studies are required to evaluate the relative risks and benefits of COXIBs in patients with IBD.
Despite epidemiological and experimental evidence strongly implicating chronic inflammation as a risk factor for CRC, surprisingly little research has directly addressed the question of how chronic inflammation results in neoplastic transformation and promotes cancer progression. It is generally thought that chronic inflammation orchestrates a tumor-supporting microenvironment that promotes tumor initiation, progression and metastasis. In a large case-control study, there was a trend for long-term NSAID consumption to protect against CRC in patients with IBD (Bernstein et al., 2002; Eaden, 2003) . In a mouse model for colitis-related carcinogenesis, dietary administration of nimesulide (COXIB) effectively suppressed the development of colonic tumor induced by azoxymethane (AOM)/DSS (Kohno et al., 2005) . These findings support the hypothesis that COX-2 might have a role in IBD-associated CRC.
COX-2 and CRC
The first evidence linking COX-2 to carcinogenesis emerged from studies on CRC (Eberhart et al., 1994) . Direct molecular evidence that COX-2 has a key role in colorectal carcinogenesis was obtained from studies in animal models. Genetic studies demonstrate that deletion of the COX-2 gene results in decreased tumor formation in both the small intestine and colon of Apc Min/ þ mice (a mouse model of CRC) (Chulada et al., 2000) as well as in Apc D716 mice, another Apc mutant model (Oshima et al., 1996) . Transgenic mice with COX-2 overexpression in the colon did not develop tumors spontaneously, but did have a higher tumor load compared with wild-type mice following AOM treatment (Al-Salihi et al., 2009) . Similar observations were found in skin and gastric cancers (Muller-Decker et al., 2002; Leung et al., 2008) . Although the data that overexpression of COX-2 initiates colorectal carcinogenesis in transgenic mouse models have not been reported, overexpression of COX-2 in transgenic mice using a murine mammary tumor virus promoter induced breast carcinoma formation (Liu et al., 2001) . Moreover, COX-2 transgenic mice driven by a bovine keratin promoter developed spontaneously pancreatic ductal adenocarcinomas, whereas treatment of these mice with celecoxib completely inhibited the tumor formation (Colby et al., 2008) . These results are consistent with human clinical and epidemiological data.
Although the focus of clinical cancer research with NSAIDs was initially on chemoprevention, the potential therapeutic use of NSAIDs in cancer also obtained considerable attention. As chemotherapeutic agents and radiation therapy enhance COX-2 protein expression in human cancer cells, which in turn results in resistance to therapy, it would be important to determine whether COXIBs enhance the chemosensitivity and radiosensitivity of tumor cells. Preclinical studies showed that celecoxib potentiated the effects of radiotherapy (Davis et al., 2004) and a combination of celecoxib with oxaliplatin had synergistic effects on inhibition of tumor growth in a mouse xenograft model of human colon cancer (Zhao et al., 2009 ). More interestingly, combined treatment with S1 (a oral fluoropyryzine drug) and a COXIB more effectively reduced liver metastasis of CRC cells than either drug alone (Tachimori et al., 2008) . A phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small-cell lung cancer was performed and showed promising results, although the study was stopped earlier than planned because of safety concerns regarding celecoxib (Aruajo et al., 2009) .
COX-2 pathways
The COX enzymes convert free arachidonic acid into prostanoids, including prostaglandins (PGs) and thromboxanes (TXs). The key regulatory step in this process is the enzymatic conversion of the arachidonic acid to PGG 2 , which is then reduced to an unstable endoperoxide intermediate, PGH 2 . PGH 2 is sequentially metabolized to five active, structurally related prostanoids, including PGE 2 , PGD 2 , PGF 2a , PGI 2 and thromboxane A 2 (TxA 2 ), in a cell type-specific manner through specific PG synthases. These bioactive lipids exert their cellular functions by binding cell-surface receptors that belong to the family of seven transmembrane G-proteincoupled rhodopsin-type receptors. These receptors are designated DP for the PGD 2 receptor, EP (EP1, EP2, EP3 and EP4) for PGE 2 receptors, FP for the PGF 2a receptor, IP for the PGI 2 receptor and TP for the TXA 2 receptor. Moreover, some PGs can also bind to nuclear receptors such as PPARs. It has been shown that the PGD 2 dehydration product 15-deoxy-
PGJ 2 (15dPGJ 2 ) is a natural ligand for the PPARg receptor (Forman et al., 1995; Kliewer et al., 1995) , while PGI 2 activates PPARd by directly binding to this receptor (Forman et al., 1997; Gupta et al., 2000) . In addition, PGE 2 has been shown to indirectly transactivate PPARd (Wang et al., 2004) . Recent studies suggest that PPARg and PPARd have an important role in modulating colorectal carcinogenesis as well as other types of cancer COX-2 in IBD and CRC D Wang and RN DuBois (Panigrahy et al., 2005; Yin et al., 2005; Wang et al., 2006b; Wang and Dubois, 2008; Zuo et al., 2009) .
In addition to conversion of free arachidonic acid into prostanoids, COX-2 is also able to metabolize endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin glycerol esters and ethanolamides, respectively (Kozak et al., 2002) . These COX-2 metabolites of endocannabinoids are inactive through cannabinoid receptors but do represent a new class of biologically active eicosanoids that modulate cellular functions, such as regulation of interleukin-2 in T cells (Rockwell et al., 2008) . Furthermore, COX-2 is required for endocannabinoid-induced cell apoptosis in CRC cell lines and keratinocytes (Patsos et al., 2005; Van Dross, 2009) . Past research has determined that PGE 2 may be a key mediator of IBD (Gould et al., 1981; MacDermott, 1994; Sheibanie et al., 2007) . In an experimental model for IBD, PGE 2 appears to have a dual effect. High levels of PGE 2 exacerbate the inflammatory process (Sheibanie et al., 2007) . On the other hand, PGE 2 signaling is required for suppressing colitis symptoms and protecting mucosal damage by maintaining the integrity of the epithelial intestinal wall, presumably through the enhancement of epithelial survival and regeneration (Jiang et al., 2007) . Moreover, a genetic study reveals that only EP4-deficient mice and not mice deficient in either EP1, EP2, EP3, DP, FP, IP or TP are more sensitive to DSS treatment and developed severe colitis (Kabashima et al., 2002) . Further studies are necessary to define the role of PGE 2 and its receptors in IBD.
Proinflammatory PGE 2 has a predominant role in promoting colorectal tumor growth. PGE 2 is the most abundant PG found in human CRC (Rigas et al., 1993) . In contrast, 15-PGDH is highly expressed in normal colon mucosa but is lost in most human CRCs (Backlund et al., 2005) . PGE 2 protects small intestinal adenomas from NSAID-induced regression in Apc Min/ þ mice (Hansen-Petrik et al., 2002) , whereas loss of 15-PGDH leads to resistance of the antitumor effects of celecoxib in an AOM mouse model (Yan et al., 2009) . Recent studies showed that PGE 2 treatment dramatically increased both small and large intestinal adenoma burden in Apc Min/ þ mice and significantly enhanced AOM-induced colon tumor incidence and multiplicity (Kawamori et al., 2003; Wang et al., 2004) . Furthermore, elevated endogenous PGE 2 by the loss of 15-PGDH promoted colon tumor growth in Apc Min/ þ and AOM mouse models (Myung et al., 2006) . In contrast, inhibition of endogenous PGE 2 by genetic deletion of mPGES-1 suppressed intestinal tumorigenesis in Apc Min/ þ and AOM models (Nakanishi et al., 2008) . The central role of PGE 2 in colorectal tumorigenesis has been further confirmed by evaluating mice with homozygous deletion of PGE 2 receptors (Watanabe et al., 1999; Sonoshita et al., 2001; Mutoh et al., 2002) .
To understand mechanism(s) underlying effects of PGE 2 on cancer progression, researchers have been investigating precisely how PGE 2 promotes tumor growth and affects signaling pathways. Several reports have shown that PGE 2 promotes colorectal tumor growth by stimulating angiogenesis, cell invasion, cell growth and inhibiting apoptosis (Wang and Dubois, 2006) . These essential cellular processes are regulated by PGE 2 -activated signaling pathways, including EGFR-PI3K-Akt, Ras-MAPK, PPARd, VEGF, Bcl-2, chemokines and their receptors (Wang and Dubois, 2006; Wang et al., 2006a) . PGE 2 also activates canonical Wnt signaling by activating Tcf-4 transcription factors by stabilizing b-catenin in CRC cells (Castellone et al., 2005) . Conversely, many of the downstream pathways of PGE 2 also upregulate COX-2 expression. Such feedback loops may amplify the activity of the COX-2 pathway and may magnify the potency of COXIBs.
Conclusions
Cardiovascular and gastrointestinal side effects have dampened enthusiasm for the use of COXIBs and NSAIDs as chemopreventive agents. However, recent studies show that celecoxib may be safe for preventing recurrence of sporadic colorectal adenomas in certain people. Further investigation will be required to assess the relative risks and benefits of COXIBs and NSAIDs in different clinical settings. The mechanism underlying the side effects of NSAIDs also remains an ongoing subject of investigation. Suppression of prostacylin production is suggested to contribute to the cardiovascular complications of COXIBs (Narasimha et al., 2007) ; however, other mechanisms are likely to be important. It appears that COXIB treatment does cause plaque instability after several months of treatment in a subset of patients at high risk for cardiovascular disease. Given that PGE 2 appears to be a dominant factor in cancer progression, more selective pharmacological inhibition of PGE 2 production downstream of COX-2 may be efficacious and result in fewer side effects. Thus, it is now crucial to evaluate whether PGE 2 receptor antagonists or inhibitors of PGE 2 synthases can prevent CRC with an improved safety profile. Of course, another option may be to modulate the expression levels of 15-PGDH.
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